Table 4. Association of exacerbation under montelukast treatment with rs2660845 genotype.

Asthma onset	Late-onset		Early-onset
Ethnicity	Europeans	Europeans	Europeans	Europeans	Europeans	Europeans	Hispanics/Latinos	African Americans
Cohorts	UKBiobank	GoSHARE (a)	GoSHARE (b)	BREATHE	Tayside RCT	PAGES	GALA II	SAGE
Odds ratio (95%CI) for exacerbation using an additive model	1.04 (0.88–1.23);	0.88 (0.58–1.34);	4.5 (0.77–26.24);	4.40 (1.77–10.96);	9.60 (1.00–92.19);	0.96 (0.43–2.15);	1.04 (0.78–1.39);	0.27 (0.09–0.80);
P-value	0.965	0.33	0.0913	0.050	0.001	0.668	0.788	0.019

Odds of exacerbation rate on montelukast using an additive model adjusted for age, gender, age at 1st montelukast prescription or age at asthma onset and BMI when significant and available.

Asthma onset is defined as early for individuals ≤ 18 years old at asthma diagnosis and late for individuals over 18 years old at asthma diagnosis.